Report Detail

Pharma & Healthcare Global Recombinant Human Erythropoietin Injection Market Growth 2022-2028

  • RnM4488436
  • |
  • 30 August, 2022
  • |
  • Global
  • |
  • 101 Pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

The global market for Recombinant Human Erythropoietin Injection is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Recombinant Human Erythropoietin Injection market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Recombinant Human Erythropoietin Injection market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Recombinant Human Erythropoietin Injection market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Recombinant Human Erythropoietin Injection market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Recombinant Human Erythropoietin Injection players cover Roche, LG Chem, Kexing Biopharm, 3SBio Group and Harbin Pharmaceutical Group Holding, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Recombinant Human Erythropoietin Injection market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Recombinant Human Erythropoietin Injection market, with both quantitative and qualitative data, to help readers understand how the Recombinant Human Erythropoietin Injection market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:
The study segments the Recombinant Human Erythropoietin Injection market and forecasts the market size by Type (0.3ml Branch, 0.6ml Branch and 1ml Branch), by Application (Renal Failure Anemia and Non Renal Anemia.), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
0.3ml Branch
0.6ml Branch
1ml Branch
Others

Segmentation by application
Renal Failure Anemia
Non Renal Anemia

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Roche
LG Chem
Kexing Biopharm
3SBio Group
Harbin Pharmaceutical Group Holding
Dong-E-E-Jiao
Humanwell Healthcare
Ncpc Genetech Biotechnology
Shandong E-hua Biotech Pharmaceutical
Intas Pharmaceuticals
PeproTech
WELLONA PHARMA
SI HUAN SHENG WU
Shanxi Weiqidaguangming Pharmaceutical

Chapter Introduction
Chapter 1: Scope of Recombinant Human Erythropoietin Injection, Research Methodology, etc.
Chapter 2: Executive Summary, global Recombinant Human Erythropoietin Injection market size (sales and revenue) and CAGR, Recombinant Human Erythropoietin Injection market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Recombinant Human Erythropoietin Injection sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Recombinant Human Erythropoietin Injection sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Recombinant Human Erythropoietin Injection market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Roche, LG Chem, Kexing Biopharm, 3SBio Group, Harbin Pharmaceutical Group Holding, Dong-E-E-Jiao, Humanwell Healthcare, Ncpc Genetech Biotechnology and Shandong E-hua Biotech Pharmaceutical, etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Recombinant Human Erythropoietin Injection Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for Recombinant Human Erythropoietin Injection by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for Recombinant Human Erythropoietin Injection by Country/Region, 2017, 2022 & 2028
  • 2.2 Recombinant Human Erythropoietin Injection Segment by Type
    • 2.2.1 0.3ml Branch
    • 2.2.2 0.6ml Branch
    • 2.2.3 1ml Branch
    • 2.2.4 Others
  • 2.3 Recombinant Human Erythropoietin Injection Sales by Type
    • 2.3.1 Global Recombinant Human Erythropoietin Injection Sales Market Share by Type (2017-2022)
    • 2.3.2 Global Recombinant Human Erythropoietin Injection Revenue and Market Share by Type (2017-2022)
    • 2.3.3 Global Recombinant Human Erythropoietin Injection Sale Price by Type (2017-2022)
  • 2.4 Recombinant Human Erythropoietin Injection Segment by Application
    • 2.4.1 Renal Failure Anemia
    • 2.4.2 Non Renal Anemia
  • 2.5 Recombinant Human Erythropoietin Injection Sales by Application
    • 2.5.1 Global Recombinant Human Erythropoietin Injection Sale Market Share by Application (2017-2022)
    • 2.5.2 Global Recombinant Human Erythropoietin Injection Revenue and Market Share by Application (2017-2022)
    • 2.5.3 Global Recombinant Human Erythropoietin Injection Sale Price by Application (2017-2022)

3 Global Recombinant Human Erythropoietin Injection by Company

  • 3.1 Global Recombinant Human Erythropoietin Injection Breakdown Data by Company
    • 3.1.1 Global Recombinant Human Erythropoietin Injection Annual Sales by Company (2020-2022)
    • 3.1.2 Global Recombinant Human Erythropoietin Injection Sales Market Share by Company (2020-2022)
  • 3.2 Global Recombinant Human Erythropoietin Injection Annual Revenue by Company (2020-2022)
    • 3.2.1 Global Recombinant Human Erythropoietin Injection Revenue by Company (2020-2022)
    • 3.2.2 Global Recombinant Human Erythropoietin Injection Revenue Market Share by Company (2020-2022)
  • 3.3 Global Recombinant Human Erythropoietin Injection Sale Price by Company
  • 3.4 Key Manufacturers Recombinant Human Erythropoietin Injection Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers Recombinant Human Erythropoietin Injection Product Location Distribution
    • 3.4.2 Players Recombinant Human Erythropoietin Injection Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Recombinant Human Erythropoietin Injection by Geographic Region

  • 4.1 World Historic Recombinant Human Erythropoietin Injection Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global Recombinant Human Erythropoietin Injection Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global Recombinant Human Erythropoietin Injection Annual Revenue by Geographic Region
  • 4.2 World Historic Recombinant Human Erythropoietin Injection Market Size by Country/Region (2017-2022)
    • 4.2.1 Global Recombinant Human Erythropoietin Injection Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global Recombinant Human Erythropoietin Injection Annual Revenue by Country/Region
  • 4.3 Americas Recombinant Human Erythropoietin Injection Sales Growth
  • 4.4 APAC Recombinant Human Erythropoietin Injection Sales Growth
  • 4.5 Europe Recombinant Human Erythropoietin Injection Sales Growth
  • 4.6 Middle East & Africa Recombinant Human Erythropoietin Injection Sales Growth

5 Americas

  • 5.1 Americas Recombinant Human Erythropoietin Injection Sales by Country
    • 5.1.1 Americas Recombinant Human Erythropoietin Injection Sales by Country (2017-2022)
    • 5.1.2 Americas Recombinant Human Erythropoietin Injection Revenue by Country (2017-2022)
  • 5.2 Americas Recombinant Human Erythropoietin Injection Sales by Type
  • 5.3 Americas Recombinant Human Erythropoietin Injection Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Recombinant Human Erythropoietin Injection Sales by Region
    • 6.1.1 APAC Recombinant Human Erythropoietin Injection Sales by Region (2017-2022)
    • 6.1.2 APAC Recombinant Human Erythropoietin Injection Revenue by Region (2017-2022)
  • 6.2 APAC Recombinant Human Erythropoietin Injection Sales by Type
  • 6.3 APAC Recombinant Human Erythropoietin Injection Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe Recombinant Human Erythropoietin Injection by Country
    • 7.1.1 Europe Recombinant Human Erythropoietin Injection Sales by Country (2017-2022)
    • 7.1.2 Europe Recombinant Human Erythropoietin Injection Revenue by Country (2017-2022)
  • 7.2 Europe Recombinant Human Erythropoietin Injection Sales by Type
  • 7.3 Europe Recombinant Human Erythropoietin Injection Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Recombinant Human Erythropoietin Injection by Country
    • 8.1.1 Middle East & Africa Recombinant Human Erythropoietin Injection Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa Recombinant Human Erythropoietin Injection Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa Recombinant Human Erythropoietin Injection Sales by Type
  • 8.3 Middle East & Africa Recombinant Human Erythropoietin Injection Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Recombinant Human Erythropoietin Injection
  • 10.3 Manufacturing Process Analysis of Recombinant Human Erythropoietin Injection
  • 10.4 Industry Chain Structure of Recombinant Human Erythropoietin Injection

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 Recombinant Human Erythropoietin Injection Distributors
  • 11.3 Recombinant Human Erythropoietin Injection Customer

12 World Forecast Review for Recombinant Human Erythropoietin Injection by Geographic Region

  • 12.1 Global Recombinant Human Erythropoietin Injection Market Size Forecast by Region
    • 12.1.1 Global Recombinant Human Erythropoietin Injection Forecast by Region (2023-2028)
    • 12.1.2 Global Recombinant Human Erythropoietin Injection Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Recombinant Human Erythropoietin Injection Forecast by Type
  • 12.7 Global Recombinant Human Erythropoietin Injection Forecast by Application

13 Key Players Analysis

  • 13.1 Roche
    • 13.1.1 Roche Company Information
    • 13.1.2 Roche Recombinant Human Erythropoietin Injection Product Offered
    • 13.1.3 Roche Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 Roche Main Business Overview
    • 13.1.5 Roche Latest Developments
  • 13.2 LG Chem
    • 13.2.1 LG Chem Company Information
    • 13.2.2 LG Chem Recombinant Human Erythropoietin Injection Product Offered
    • 13.2.3 LG Chem Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 LG Chem Main Business Overview
    • 13.2.5 LG Chem Latest Developments
  • 13.3 Kexing Biopharm
    • 13.3.1 Kexing Biopharm Company Information
    • 13.3.2 Kexing Biopharm Recombinant Human Erythropoietin Injection Product Offered
    • 13.3.3 Kexing Biopharm Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 Kexing Biopharm Main Business Overview
    • 13.3.5 Kexing Biopharm Latest Developments
  • 13.4 3SBio Group
    • 13.4.1 3SBio Group Company Information
    • 13.4.2 3SBio Group Recombinant Human Erythropoietin Injection Product Offered
    • 13.4.3 3SBio Group Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 3SBio Group Main Business Overview
    • 13.4.5 3SBio Group Latest Developments
  • 13.5 Harbin Pharmaceutical Group Holding
    • 13.5.1 Harbin Pharmaceutical Group Holding Company Information
    • 13.5.2 Harbin Pharmaceutical Group Holding Recombinant Human Erythropoietin Injection Product Offered
    • 13.5.3 Harbin Pharmaceutical Group Holding Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 Harbin Pharmaceutical Group Holding Main Business Overview
    • 13.5.5 Harbin Pharmaceutical Group Holding Latest Developments
  • 13.6 Dong-E-E-Jiao
    • 13.6.1 Dong-E-E-Jiao Company Information
    • 13.6.2 Dong-E-E-Jiao Recombinant Human Erythropoietin Injection Product Offered
    • 13.6.3 Dong-E-E-Jiao Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 Dong-E-E-Jiao Main Business Overview
    • 13.6.5 Dong-E-E-Jiao Latest Developments
  • 13.7 Humanwell Healthcare
    • 13.7.1 Humanwell Healthcare Company Information
    • 13.7.2 Humanwell Healthcare Recombinant Human Erythropoietin Injection Product Offered
    • 13.7.3 Humanwell Healthcare Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.7.4 Humanwell Healthcare Main Business Overview
    • 13.7.5 Humanwell Healthcare Latest Developments
  • 13.8 Ncpc Genetech Biotechnology
    • 13.8.1 Ncpc Genetech Biotechnology Company Information
    • 13.8.2 Ncpc Genetech Biotechnology Recombinant Human Erythropoietin Injection Product Offered
    • 13.8.3 Ncpc Genetech Biotechnology Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.8.4 Ncpc Genetech Biotechnology Main Business Overview
    • 13.8.5 Ncpc Genetech Biotechnology Latest Developments
  • 13.9 Shandong E-hua Biotech Pharmaceutical
    • 13.9.1 Shandong E-hua Biotech Pharmaceutical Company Information
    • 13.9.2 Shandong E-hua Biotech Pharmaceutical Recombinant Human Erythropoietin Injection Product Offered
    • 13.9.3 Shandong E-hua Biotech Pharmaceutical Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.9.4 Shandong E-hua Biotech Pharmaceutical Main Business Overview
    • 13.9.5 Shandong E-hua Biotech Pharmaceutical Latest Developments
  • 13.10 Intas Pharmaceuticals
    • 13.10.1 Intas Pharmaceuticals Company Information
    • 13.10.2 Intas Pharmaceuticals Recombinant Human Erythropoietin Injection Product Offered
    • 13.10.3 Intas Pharmaceuticals Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.10.4 Intas Pharmaceuticals Main Business Overview
    • 13.10.5 Intas Pharmaceuticals Latest Developments
  • 13.11 PeproTech
    • 13.11.1 PeproTech Company Information
    • 13.11.2 PeproTech Recombinant Human Erythropoietin Injection Product Offered
    • 13.11.3 PeproTech Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.11.4 PeproTech Main Business Overview
    • 13.11.5 PeproTech Latest Developments
  • 13.12 WELLONA PHARMA
    • 13.12.1 WELLONA PHARMA Company Information
    • 13.12.2 WELLONA PHARMA Recombinant Human Erythropoietin Injection Product Offered
    • 13.12.3 WELLONA PHARMA Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.12.4 WELLONA PHARMA Main Business Overview
    • 13.12.5 WELLONA PHARMA Latest Developments
  • 13.13 SI HUAN SHENG WU
    • 13.13.1 SI HUAN SHENG WU Company Information
    • 13.13.2 SI HUAN SHENG WU Recombinant Human Erythropoietin Injection Product Offered
    • 13.13.3 SI HUAN SHENG WU Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.13.4 SI HUAN SHENG WU Main Business Overview
    • 13.13.5 SI HUAN SHENG WU Latest Developments
  • 13.14 Shanxi Weiqidaguangming Pharmaceutical
    • 13.14.1 Shanxi Weiqidaguangming Pharmaceutical Company Information
    • 13.14.2 Shanxi Weiqidaguangming Pharmaceutical Recombinant Human Erythropoietin Injection Product Offered
    • 13.14.3 Shanxi Weiqidaguangming Pharmaceutical Recombinant Human Erythropoietin Injection Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.14.4 Shanxi Weiqidaguangming Pharmaceutical Main Business Overview
    • 13.14.5 Shanxi Weiqidaguangming Pharmaceutical Latest Developments

14 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on Recombinant Human Erythropoietin Injection. Industry analysis & Market Report on Recombinant Human Erythropoietin Injection is a syndicated market report, published as Global Recombinant Human Erythropoietin Injection Market Growth 2022-2028. It is complete Research Study and Industry Analysis of Recombinant Human Erythropoietin Injection market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
3,246.42
6,492.84
3,733.20
7,466.40
529,236.00
1,058,472.00
298,326.60
596,653.20
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report